ArticleCancer immunology, immunotherapy : CII2022

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.

Xiangling Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.